{"id":"vk2735","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By simultaneously activating GLP-1 and glucagon receptors, VK2735 enhances insulin secretion, reduces appetite, increases energy expenditure, and promotes lipolysis. This dual mechanism is designed to produce greater weight loss and metabolic benefits compared to GLP-1 monotherapy, with potential advantages in glycemic control and cardiovascular outcomes.","oneSentence":"VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:45.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity or overweight with weight-related comorbidities"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07104383","phase":"PHASE3","title":"VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)","status":"RECRUITING","sponsor":"Viking Therapeutics, Inc.","startDate":"2025-06-23","conditions":"Weight Loss","enrollment":1100},{"nctId":"NCT07104500","phase":"PHASE3","title":"VK2735 for Weight Management Phase 3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viking Therapeutics, Inc.","startDate":"2025-06-23","conditions":"Weight Loss","enrollment":4500},{"nctId":"NCT06828055","phase":"PHASE2","title":"VK2735 for Weight Management Phase 2 (Venture Oral Dosing)","status":"COMPLETED","sponsor":"Viking Therapeutics, Inc.","startDate":"2024-12-18","conditions":"Weight Loss","enrollment":280},{"nctId":"NCT05203237","phase":"PHASE1","title":"Phase 1 Study to Evaluate the Safety and Tolerability of VK2735","status":"COMPLETED","sponsor":"Viking Therapeutics, Inc.","startDate":"2021-12-14","conditions":"Weight Loss, NASH","enrollment":92},{"nctId":"NCT06068946","phase":"PHASE2","title":"VK2735 for Weight Management Phase 2","status":"COMPLETED","sponsor":"Viking Therapeutics, Inc.","startDate":"2023-08-31","conditions":"Weight Loss","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VK2735","genericName":"VK2735","companyName":"Viking Therapeutics, Inc.","companyId":"viking-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters. Used for Obesity or overweight with weight-related comorbidities, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}